A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas
暂无分享,去创建一个
A. Lagares | A. Hernández-Laín | A. Ramos | Á. Pérez-Núñez | A. Hilario | J. Sepúlveda | J. Millán | E. Salvador | V. Rodriguez-Gonzalez | J. M. Sepúlveda | A. Hilario | E. Salvador | J. M. Millán | A. Hernández-Laín | A. Lagares | J. Sepúlveda
[1] G. Fuller,et al. Moving toward molecular classification of diffuse gliomas in adults , 2012, Neurology.
[2] Nader Sanai,et al. The Value of Glioma Extent of Resection in the Modern Neurosurgical Era , 2012, Front. Neur..
[3] C. Davatzikos,et al. Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables , 2012, American Journal of Neuroradiology.
[4] J. Boxerman,et al. The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.
[5] M. Rosenthal,et al. Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis? , 2012, Journal of Clinical Neuroscience.
[6] A. Lagares,et al. The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas , 2012, American Journal of Neuroradiology.
[7] T. Mikkelsen,et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.
[8] M S Brown,et al. Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.
[9] Stephen Yip,et al. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers , 2010, The Lancet Neurology.
[10] F. Ducray,et al. Prognostic markers in gliomas. , 2010, Future oncology.
[11] M. Law,et al. Magnetic resonance perfusion and permeability imaging in brain tumors. , 2009, Neuroimaging clinics of North America.
[12] F. Ducray,et al. Diagnostic and prognostic markers in gliomas , 2009, Current opinion in oncology.
[13] K. Schmainda,et al. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.
[14] J. Barnholtz-Sloan,et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.
[15] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[16] C. Decaestecker,et al. Apparent Diffusion Coefficient and Cerebral Blood Volume in Brain Gliomas: Relation to Tumor Cell Density and Tumor Microvessel Density Based on Stereotactic Biopsies , 2008, American Journal of Neuroradiology.
[17] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[18] G Johnson,et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. , 2007, AJNR. American journal of neuroradiology.
[19] R. Newson. Confidence Intervals for Rank Statistics: Somers’ D and Extensions , 2006 .
[20] S. Cha,et al. Update on brain tumor imaging: from anatomy to physiology. , 2006, AJNR. American journal of neuroradiology.
[21] Glyn Johnson,et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.
[22] C. Meyer,et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[24] I. Ercan,et al. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. , 2005, Clinical radiology.
[25] Glyn Johnson,et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.
[26] Glyn Johnson,et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.
[27] K. Kono,et al. The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.
[28] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[29] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[30] Susan M. Chang,et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.
[31] L. D.,et al. Brain tumors , 2005, Psychiatric Quarterly.
[32] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.